Objective To investigate relationship between androgen receptor (AR) and clinicopathologic features of patients with triple negative breast cancer (TNBC) in Xinjiang. Methods The clinical data of Han and Uygur patients with TNBC from the First Affiliated Hospital of Xinjiang Medical University from December 2012 to December 2016 were retrospectively analyzed. And the expression of the AR and the clinicopathologic features of the patients with TNBC were extracted. The results were analyzed by SPSS 19.0. Results A total of 178 patients with TNBC were included, including 127 Han and 51 Uygur patients. The positive rate of the AR expression in the 178 patients with TNBC was 21.3% (38/178), which was significantly related to the expression of Ki-67 (χ2=15.196, P<0.001), was not related to the ethnicity (χ2=0.203, P=0.688), age (χ2=0.221, P=0.715), tumor size (χ2=0.047, P=0.855), lymph node status (χ2=0.874, P=0.354), or histological grade (χ2=0.001, P=1.000). And there were no statistically significant differences in the clinicopathologic features between the Han patients with TNBC and the Uygur patients with TNBC. Conclusion AR positive expression is related to Ki-67, but clinicopathologic features have no significant differences between Han and Uygur patients with TNBC in Xingjinag.
ObjectiveTo detect protein expression of androgen receptor (AR) in patients with estrogen receptor (ER)-positive primary breast cancer and investigate its significances on prognosis.MethodsThe clinicopathologic data of female patients with ER-positive primary breast cancer in the Affiliated Hospital of Southwest Medical University from January 2012 to December 2012 were retrospectively analyzed. The AR protein expression in the breast cancer tissue was detected by the immunohistochemistry. The relationship between the AR protein expression and the clinicopathologic characteristics such as the age, tumor diameter, invasive biological behavior, molecular typing or the survival after the operation was analyzed.ResultsThe positive rate of AR protein expression was 58.5% (76/130) in the patients with ER-positive primary breast cancer. The positive rates of AR protein expression in the patients with the low differentiation, clinical stage Ⅲ+Ⅳ, p53 positive, neurovascular invasion, and lymph node metastasis were significantly lower than those in the patients with the moderate and high differentiations, clinical stage Ⅰ +Ⅱ, p53 negative, without neurovascular invasion, and without lymph node metastasis (P<0.050). The positive rate of AR protein expression was not correlated with the age, menstrual status, tumor diameter, progesterone receptor and Her-2 statuses, Ki-67, or molecular typing (P>0.050). The 3-year and 5-year overall survival and tumor-free survival of the AR-positive patients were significantly higher than those of the AR-negative patients (P<0.050). The 5-year cumulative total survival and tumor-free survival of the AR-positive patients were significantly better than those of the AR-negative patients (χ2=8.134, P=0.004; χ2=9.150, P=0.002).ConclusionsPatient with AR protein positive expression in ER-positive breast cancer has a better differentiation, lower clinical stage, and weaker invasiveness. Long-term survival of patient with AR protein positive expression after standardized treatment is also better than that of patient with AR protein negative expression. It might provide an important additional information on prognosis and become a promising object for targeted therapy.